Royce & Associates’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Royce & Associates’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,115	Closed	-$39K	–	1057
2021 Q1	$39K	Buy	+12,115	New	+$49.8K	﹤0.01%	1011
2020 Q3	–	Sell	-5,012	Closed	-$34K	–	1191
2020 Q2	$34K	Sell	5,012 -1,172	-19%	-$5.74K	﹤0.01%	1080
2020 Q1	$20K	Buy	+6,184	New	+$32.9K	﹤0.01%	1091
2019 Q3	–	Sell	-9,479	Closed	-$36K	–	1192
2019 Q2	$36K	Buy	+9,479	New	+$31.5K	﹤0.01%	1063
2019 Q1	–	Sell	-2,745	Closed	-$21K	–	1200
2018 Q4	$21K	Buy	+2,745	New	+$22K	﹤0.01%	1101

Other funds holding RVLP

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Royce & Associates's RVLP Position: Q2 2021 in Review

Royce & Associates sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2021, closing a stake of 12,115 shares — an estimated $39K sold.

Royce & Associates first reported a position in RVLP in Q4 2018 and held it in 5 quarters. The position peaked at $39K in Q1 2021. 46 funds tracked by Wall St. Rank hold RVLP as of Q2 2021.

Royce & Associates reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2021 after selling out during the quarter.
Royce & Associates sold 12,115 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2021, an estimated $39K.
Royce & Associates first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 5 quarters.
Royce & Associates's RVL Pharmaceuticals plc Ordinary Shares position peaked at $39K in Q1 2021.
46 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2021.

Based on Royce & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.